Diana Păun
medic primar endocrinolog, asistent universitar Institutul Naţional de Endocrinologie “C.I.Parhon”, Bucureşti
Abstract
Osteoporosis is a skeletal disorder in which bone strength is compromised due to loss of bone density and bone quality. Osteoporosis is the most commonly occuring bone disease, and it is anticipated that the prevalence of osteoporosis will increase as the women population ages with a consequent increase in fracture risk. Risedronate have demonstrated efficacy in reducing the incidence of vertebral and non-vertebral fractures. Risedronate has been proven to provide fast and sustained vertebral and nonvertebral fracture reduction in postmenopausal women with established osteoporosis.